138 related articles for article (PubMed ID: 31376383)
21. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.
Klemke CD; Fritzsching B; Franz B; Kleinmann EV; Oberle N; Poenitz N; Sykora J; Banham AH; Roncador G; Kuhn A; Goerdt S; Krammer PH; Suri-Payer E
Leukemia; 2006 Jun; 20(6):1123-9. PubMed ID: 16557241
[TBL] [Abstract][Full Text] [Related]
22. Membrane raft-dependent regulation of phospholipase Cgamma-1 activation in T lymphocytes.
Verí MC; DeBell KE; Seminario MC; DiBaldassarre A; Reischl I; Rawat R; Graham L; Noviello C; Rellahan BL; Miscia S; Wange RL; Bonvini E
Mol Cell Biol; 2001 Oct; 21(20):6939-50. PubMed ID: 11564877
[TBL] [Abstract][Full Text] [Related]
23. Src homology 2 domain-containing leukocyte phosphoprotein of 76 kDa and phospholipase C gamma 1 are required for NF-kappa B activation and lipid raft recruitment of protein kinase C theta induced by T cell costimulation.
Dienz O; Möller A; Strecker A; Stephan N; Krammer PH; Dröge W; Schmitz ML
J Immunol; 2003 Jan; 170(1):365-72. PubMed ID: 12496421
[TBL] [Abstract][Full Text] [Related]
24. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome.
Krejsgaard T; Gjerdrum LM; Ralfkiaer E; Lauenborg B; Eriksen KW; Mathiesen AM; Bovin LF; Gniadecki R; Geisler C; Ryder LP; Zhang Q; Wasik MA; Odum N; Woetmann A
Leukemia; 2008 Dec; 22(12):2230-9. PubMed ID: 18769452
[TBL] [Abstract][Full Text] [Related]
25. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of Cbl and 70Z/3 Cbl on T cell receptor-induced phospholipase Cgamma-1 activity.
Graham LJ; DeBell KE; Verí M; Stoica B; Mostowski H; Bonvini E; Rellahan B
FEBS Lett; 2000 Mar; 470(3):273-80. PubMed ID: 10745081
[TBL] [Abstract][Full Text] [Related]
27. Selective modulation of nuclear factor of activated T-cell function in restenosis by a potent bipartite peptide inhibitor.
Yu H; Bot I; Sliedregt K; Xu X; Bot M; van Heiningen SH; van der Marel GA; Bennett MR; Overkleeft H; van Berkel TJ; Biessen EA
Circ Res; 2012 Jan; 110(2):200-10. PubMed ID: 22116820
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic tools in Sezary syndrome.
Möbs M; Knott M; Fritzen B; Pullmann S; Sterry W; Assaf C
G Ital Dermatol Venereol; 2010 Jun; 145(3):385-91. PubMed ID: 20461046
[TBL] [Abstract][Full Text] [Related]
29. PKCtheta is necessary for efficient activation of NFkappaB, NFAT, and AP-1 during positive selection of thymocytes.
Gruber T; Pfeifhofer-Obermair C; Baier G
Immunol Lett; 2010 Aug; 132(1-2):6-11. PubMed ID: 20433868
[TBL] [Abstract][Full Text] [Related]
30. Differential roles of PKC-theta in the regulation of intracellular calcium concentration in primary T cells.
Manicassamy S; Sadim M; Ye RD; Sun Z
J Mol Biol; 2006 Jan; 355(3):347-59. PubMed ID: 16309697
[TBL] [Abstract][Full Text] [Related]
31. NOTCH1 signaling as a therapeutic target in Sézary syndrome.
van der Fits L; Qin Y; Out-Luiting JJ; Vermeer KG; Whittaker S; van Es JH; Tensen CP; Vermeer MH
J Invest Dermatol; 2012 Dec; 132(12):2810-7. PubMed ID: 22718117
[TBL] [Abstract][Full Text] [Related]
32. Sézary syndrome: old enigmas, new targets.
Nicolay JP; Felcht M; Schledzewski K; Goerdt S; Géraud C
J Dtsch Dermatol Ges; 2016 Mar; 14(3):256-64. PubMed ID: 26972187
[TBL] [Abstract][Full Text] [Related]
33. Sézary syndrome originates from heavily mutated hematopoietic progenitors.
Harro CM; Sprenger KB; Chaurio RA; Powers JJ; Innamarato P; Anadon CM; Zhang Y; Biswas S; Mandal G; Mine JA; Cortina C; Nagy MZ; Martin AL; Handley KF; Borjas GJ; Chen PL; Pinilla-Ibarz J; Sokol L; Yu X; Conejo-Garcia JR
Blood Adv; 2023 Sep; 7(18):5586-5602. PubMed ID: 37531660
[TBL] [Abstract][Full Text] [Related]
34. A dynamic constitutive and inducible binding of c-Cbl by PLCgamma1 SH3 and SH2 domains (negatively) regulates antigen receptor-induced PLCgamma1 activation in lymphocytes.
Rellahan BL; Graham LJ; Tysgankov AY; DeBell KE; Veri MC; Noviello C; Bonvini E
Exp Cell Res; 2003 Sep; 289(1):184-94. PubMed ID: 12941616
[TBL] [Abstract][Full Text] [Related]
35. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
[TBL] [Abstract][Full Text] [Related]
36. Phospholipase Cgamma2 is critical for Dectin-1-mediated Ca2+ flux and cytokine production in dendritic cells.
Xu S; Huo J; Lee KG; Kurosaki T; Lam KP
J Biol Chem; 2009 Mar; 284(11):7038-46. PubMed ID: 19136564
[TBL] [Abstract][Full Text] [Related]
37. Pleiotropic contributions of phospholipase C-gamma1 (PLC-gamma1) to T-cell antigen receptor-mediated signaling: reconstitution studies of a PLC-gamma1-deficient Jurkat T-cell line.
Irvin BJ; Williams BL; Nilson AE; Maynor HO; Abraham RT
Mol Cell Biol; 2000 Dec; 20(24):9149-61. PubMed ID: 11094067
[TBL] [Abstract][Full Text] [Related]
38. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.
Wang Y; Su M; Zhou LL; Tu P; Zhang X; Jiang X; Zhou Y
Blood; 2011 Apr; 117(14):3826-35. PubMed ID: 21270445
[TBL] [Abstract][Full Text] [Related]
39. Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome.
Woollard WJ; Pullabhatla V; Lorenc A; Patel VM; Butler RM; Bayega A; Begum N; Bakr F; Dedhia K; Fisher J; Aguilar-Duran S; Flanagan C; Ghasemi AA; Hoffmann RM; Castillo-Mosquera N; Nuttall EA; Paul A; Roberts CA; Solomonidis EG; Tarrant R; Yoxall A; Beyers CZ; Ferreira S; Tosi I; Simpson MA; de Rinaldis E; Mitchell TJ; Whittaker SJ
Blood; 2016 Jun; 127(26):3387-97. PubMed ID: 27121473
[TBL] [Abstract][Full Text] [Related]
40. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
